Acute Coronary Syndrome Market Insight, Epidemiology, And Market Forecast - 2036 - Reveals Why 2.2 Million Annual Cases Still Rely On Repurposed Antithrombotics, Not Disease-Modifying Therapy
Dublin, Sept. 04, 2026 (GLOBE NEWSWIRE) -- The "Acute Coronary Syndrome - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
According to the report, total incident cases of ACS across the seven major markets (7MM) were approximately 2.2 million in 2025, with the highest incidence recorded in the United States, where roughly 1.3 million new cases occurred that year. Acute Myocardial Infarction (AMI) accounted for a higher share of ACS cases than Unstable Angina, approximately 835,000 cases in the U.S. alone with NSTEMI presentations making up roughly 75% of AMI cases versus around 25% for STEMI.
Despite this scale, the report finds that most pharmaceutical development has centered on AMI or the broader ACS category rather than unstable angina, and that treatment continues to rely heavily on established antiplatelet agents, anticoagulants, beta-blockers, nitrates, statins, ACE inhibitors/ARBs, and calcium channel blockers rather than disease-specific therapies.
Market Size and Forecast
The report estimates the 2025 ACS market size at approximately USD 2.70 billion, projected to reach approximately USD 9.00 billion by 2036, reflecting an 11.5% CAGR. The United States captured the largest share of the market in 2025 at approximately USD 2.20 billion, with antiplatelet agents generating the highest revenue among all therapy classes in the country that year.
A Shift Toward Targeted, Mechanism-Driven Therapy
The report highlights a growing emphasis on inflammation-targeting and optimized antithrombotic strategies. In June 2023, the FDA approved LODOCO (colchicine), developed by AGEPHA Pharma, as the first targeted anti-inflammatory therapy for atherosclerotic cardiovascular disease, demonstrating a roughly 31% reduction in cardiovascular events versus placebo. LODOCO carries an annual cost of USD 5,940 per patient.
The emerging pipeline includes Selatogrel (Idorsia Pharmaceuticals and Viatris), a fast-acting, self-administered P2Y12 inhibitor delivered via autoinjector and designed to protect heart muscle in the earliest phase of a myocardial infarction; Dutogliptin (Recardio); Ziltivekimab (Novo Nordisk), with data readouts expected between 2026 and 2027 across three clinical settings; and FDY-5301 (Faraday Pharmaceuticals). Per Idorsia's Annual Report 2025, late-stage programs for selatogrel continue progressing toward important readouts beginning at the end of 2026.
Unmet Needs
The report identifies several critical gaps in current ACS care, including delayed or missed diagnosis particularly in atypical presentations the need for better risk stratification and personalized treatment, poor control of modifiable risk factors such as diabetes and hypertension, high risk of recurrence despite existing therapies, limited awareness and delays in accessing timely care, and suboptimal long-term treatment adherence.
Report Scope
The report covers disease background, diagnosis, and treatment algorithms; epidemiology segmented by country, gender, and ACS type across the 7MM (2022-2036); marketed and emerging drug profiles including regulatory milestones, clinical development, and analyst views; market size and forecast by therapy and geography; unmet needs; SWOT and conjoint analysis; KOL views from centers including the University School of Medicine in Atlanta, the Berlin Institute of Health at Charité, and the University of Nottingham; and market access and reimbursement analysis across the U.S., EU4, UK, and Japan.
A selection of companies mentioned in this report includes, but is not limited to:
- AGEPHA Pharma Amgen Regeneron Sanofi Idorsia Pharmaceuticals Viatris Faraday Pharmaceuticals Novo Nordisk
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment